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Abstract
Background—Previous studies have demonstrated, and replicated, an association between
single nucleotide polymorphisms (SNPs) within the GABRA2 gene and risk for alcohol
dependence. The present study examines the association of a GABRA2 SNP with another
definition of alcohol involvement and with the effects of psychosocial treatment.
Methods—European-American subjects (n=812, 73.4% male) provided DNA samples for the
analysis. All were participants in Project MATCH, a multi-center randomized clinical trial
evaluating the efficacy of three types of psychosocial treatment for alcoholism: Cognitive
Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), or Twelve Step
Facilitation (TSF). The daily probabilities of drinking and heavy drinking were estimated during
the 12-week treatment and 12-month post-treatment periods.
Results—Subjects homozygous for the allele associated with low risk for alcohol dependence in
previous studies had lower daily probabilities of drinking and heavy drinking in the present study.
This low-risk allele was also associated with a greater difference in drinking outcomes between
the treatments. In addition, it enhanced the relative superiority of TSF over CBT and MET.
Population stratification was excluded as a confound using ancestry informative marker analysis.
Conclusions—The assessment of genetic vulnerability may be relevant to studies of the efficacy
of psychosocial treatment: GABRA2 genotype modifies the variance in drinking and can therefore
moderate power for resolving differences between treatments.
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INTRODUCTION
Alcohol dependence (AD), a common disorder associated with substantial adverse medical
and psychosocial consequences (Caetano and Cunradi 2002; Grant et al., 2004), has been
shown to be largely (i.e., 52–64%) heritable (Kendler 2001). Efforts to identify genes that
increase risk for the disorder have included genome-wide linkage scans, which implicated a
region on chromosome 4p12. The region contains a cluster of genes encoding subunits of the
GABA-A receptor (Long et al., 1998; Reich et al., 1998,). Edenberg et al. (Edenberg et al.,
2004) mapped this gene cluster in detail in multiplex alcoholism families and found
significant associations for multiple markers in the gene encoding the GABAAα-2 subunit
[GABRA2 (MIM 137140)] and for a single marker in the adjacent GABRG1 (MIM 137166)
gene, which encodes the GABAAγ-1 subunit. The association of GABRA2 markers with AD
was subsequently replicated wholly or in part in five independent studies (Covault et al.,
2004; Enoch et al., 2006; Fehr et al., 2006; Lappalainen et al., 2005); in most of these
studies, an association of AD with a haplotype block spanning the central and 3′-regions of
GABRA2 was observed.
The present study examined a representative marker of the AD-associated haplotype block
in GABRA2 using DNA samples from alcohol-dependent patients who participated in
Project MATCH, a psychotherapy study conducted at 10 sites around the United States
(Project MATCH Research Group 1997; Project MATCH Research Group 1997). The
project included two parallel, but independent, clinical arms in which patients were recruited
from outpatient settings (n = 952; 72% male) or aftercare settings following inpatient or day
hospital treatment (n = 774; 80% male). Each of the two arms involved random assignment
to one of three manual-guided, individually delivered treatments: Motivational Enhancement
Therapy (MET), Cognitive Behavioral Therapy (CBT), or Twelve-Step Facilitation (TSF).
For the primary analyses (Project MATCH Research Group 1997; Project MATCH
Research Group 1997), alcohol consumption during each of the prior 90 days was assessed
at baseline, at the end of the 12-week treatment period, and quarterly over a 1-year post-
treatment period using the Form 90 Interview (Tonigan et al., 1997).
One reason for examining the GABRA2 gene in Project MATCH patients was to determine
if its predictive validity generalized beyond alcohol dependence to other measures of
drinking behavior. More specifically, the present analysis tested the association of genotype
with the daily probabilities of drinking and heavy drinking (men: ≥5 drinks/day; women: ≥4
drinks/day).
A second reason for examining variation in GABRA2 in these patients was to determine if it
would predict treatment outcome. Although GABRA2 has not yet been studied as a treatment
moderator, the existing literature provides indirect support for the hypothesis. GABRA2 has,
for example, been associated with an excess amount of high frequency, fast β activity in the
spontaneous electroencephalogram (Edenberg et al., 2004). Fast β EEG activity has, in other
studies, been linked to poor outcome in alcohol- and drug-dependent individuals (Bauer
1994; Bauer 2001; Prichep et al., 1999; Saletu-Zyhlarz et al., 2004; Winterer et al., 1998). In
addition, GABRA2 genotype has been associated with Conduct Disorder problems (Dick et
al., 2006,) which have, in turn, also been linked to poor outcome (Myers et al., 1995). Thus,
the potential exists for GABRA2 genotype to join the long list of clinical [e.g., severity of
dependence (Bottlender and Soyka 2005), comorbid psychopathology (Ciraulo et al., 2003;
Kushner et al., 2005; Pettinati et al., 1999)], psychological [e.g., self-efficacy, coping skills
(Ciraulo et al., 2003; Maisto et al., 2000)], or biological [e.g., fast β EEG activity, sleep
disturbance (Bauer 1994; Bauer 2001; Prichep et al., 1999; Saletu-Zyhlarz et al., 2004;
Winterer et al., 1998; Brower et al., 1998; Brower et al., 2001; Clark et al., 1998;
Drummond et al., 1998; Gillin et al., 1994)] variables for which a relationship to substance
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abuse treatment outcome has been demonstrated. If an association with GABRA2 could be
demonstrated, then the field may benefit from an expansion of the theoretical framework for
interpreting the causes of treatment failure. As a result, new models for treatment matching
may emerge.
PATIENTS AND METHODS
Patients
Eight hundred twelve self-identified European-American patients from Project MATCH
provided blood for DNA extraction and were included in the analysis. Five hundred forty
patients were recruited from outpatient settings and 272 from aftercare settings. The patient
sample can be generally described (Table 1) as 73.4% male and averaging 40.8 years of age.
They completed, on average, 13.5 yrs of education.
Pre-treatment alcohol consumption was high. Patients consumed an average of 15.1 drinks
per drinking day and were abstinent on only 30.1% of all days during the 90-day pre-
treatment period. The typical patient met 6 of the 9 DSM-III-R (American Psychiatric
Association 1987) criteria for a diagnosis of alcohol dependence.
Despite their relatively high level of dependence on alcohol, patients had relatively few
comorbid psychiatric disorders. For example, 10% of patients met DSM-III-R criteria
(American Psychiatric Association, 1987) for a diagnosis of Antisocial Personality Disorder.
In addition, the average level of psychiatric severity (i.e., measuring not addiction, per se,
but other psychiatric problems in the context of substance abuse; McLellan et al. 1983) on
the Addiction Severity Index was in lower third of the subscale score range of 0.0–1.0.
Similarly, the mean score (10.5) on the Beck Depression Inventory (Beck et al., 1961)
indicated a low level of depressive symptoms.
Genotyping
DNA was extracted from archived samples of peripheral blood using a commercial kit
(PureGene™ Gentra, Minneapolis, MN). A synonymous, exonic SNP (rs279858)
representative of and located in the middle of the GABRA2 haplotype block, previously
shown to be associated with AD (Covault et al., 2004) and with subjective responses to
alcohol (Pierucci-Lagha et al., 2005), was genotyped using a closed-tube fluorescent
TaqMan 5′-nuclease allelic discrimination assay using MGB-probes (Vic-
TGAGCTACTGATTTCTTCCCAT and 6FAM-TGAGCTACTGATTTTTTCCCAT;
chromosome 4 plus strand sequences) and primers (GAAGCAACTTATTTGGCATTGTCA
and TCTGGACTCCAGATACCTTTTTTCA) designed using Primer Express v2.0 software
[Applied Biosystems Inc. (ABI) Foster City, CA]. Fluorescence plate reads and genotype
calls were made using ABI 7700 and 7500 Sequence Detection Systems. Ten ng of genomic
DNA was PCR amplified in 96-well plates using a 10 μl reaction volume for 40 cycles at
94°C for 15s followed by 60°C for 60s. Repeat genotyping was carried out for 12% of
samples with no genotype discrepancies. PCR amplifications failed or provided ambiguous
genotype results from 4 subjects (excluded from analysis).
To evaluate population stratification as a potential bias in the association analyses, we also
genotyped a panel of 34 short tandem repeat ancestry informative markers (AIMs), as
described previously (Yang et al., 2005; Covault et al., 2007).
Statistical Analysis
Despite a substantial sample size, the N was unfortunately not sufficient to support an
analysis wherein genotype could be stratified by three levels, and further stratified by three
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levels of treatment assignment and two levels of gender. Instead, genotype was stratified by
two levels: homozygotes for the low alcohol dependence risk A-allele (which comprises the
low-risk genotype group) versus carriers of the AD-associated G-allele (which comprises the
high-risk genotype group). This strategy is consistent with the grouping scheme employed in
our prior studies (Covault et al., 2004; Lappalainen et al., 2005) which found an association
of the G-allele with risk of alcohol dependence.
The first stage of the analysis included tests of the effects of GABRA2 genotype, treatment
arm, and treatment assignment on demographic and psychological variables. In addition,
differences in substance use during the 90-day pre-treatment period were tested. Pearson’s
χ2 test was used to evaluate group equivalence on categorical variables. Three-factor
ANOVAs (genotype by treatment assignment by treatment arm) were used to evaluate
equivalence on continuous variables.
In the second analysis stage, the SAS® statistical software (Version 9.1.3) procedure
GENMOD employed maximum likelihood estimation to fit log-linear models to longitudinal
binary response data. Instances of incomplete data were rare. Across the combined total of
365,400 days of assessment, <1% of data were missing.
We used the software program STRUCTURE v2.1 (Pritchard et al., 2000; Falush et al.,
2003) and genotype results from the AIMs, we generated estimates of the proportion of
genetic ancestry for each subject (inferred to be primarily African or European based on
subject self-report). The sample for this analysis included 750 of the subjects from the
present study, together with AIM data from more than 1,000 additional European-American
or African-American subjects to yield reliable estimates of ancestry proportions (see Covault
et al. 2007). Simulations used 100,000 burn-ins followed by 500,000 runs and a population
parameter K=2.
In separate analyses, we used SAS, Proc GENMOD to estimate the probabilities of any
drinking and heavy drinking (i.e., ≥4 drinks in a day for women and ≥5 drinks in a day for
men) on each of the 450 days from the beginning of treatment through the one-year follow-
up period. Both analyses included terms to extract variance associated with Gender,
Treatment Arm (outpatient versus aftercare), and a linear trend over Time. The models also
included terms permitting tests of the main and interaction effects of GABRA2 Genotype,
Treatment Day, and Treatment Assignment (CBT, MET, TSF). Odds ratios (ORs) and their
respective likelihood statistics (χ2) were calculated to permit a formal test of the significance
of these main and interaction effects.
RESULTS
GABRA2 Genotype and Allele Frequencies
The sample included 136 G-allele homozygotes (16.7%), 411 heterozygotes (50.6%) and
265 A-allele homozygotes (32.6%), a distribution that is consistent with Hardy-Weinberg
equilibrium expectations (p = .55). The frequencies of the G- and A-alleles were .421 and .
579, respectively.
Effects of GABRA2 genotype on pre-treatment characteristics
Analyses of pre-treatment characteristics revealed more drinks per drinking day (F=60.6, p<.
001) and a lower percentage of days abstinent (F=6.2, p<.02) among patients receiving
treatment in the aftercare versus outpatient arms of the project. The analyses, however,
yielded no other significant effects of treatment arm on pre-treatment characteristics.
Importantly, the analyses also revealed no significant differences among patients as a
function of the treatment assignment, and no significant effects of genotype or interactions
Bauer et al. Page 4
Alcohol Clin Exp Res. Author manuscript; available in PMC 2011 September 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of genotype with either treatment assignment (Table 1) or treatment arm. Further, the
ancestry proportion of the subjects was 98.5% European (SD = 2.6%), with no main or
interactive effects of sex, genotype group, treatment arm (aftercare vs. outpatient), or
treatment assignment (CBT vs. MET vs. TSF). Thus, it was deemed unnecessary to enter
pre-treatment variables or ancestry proportion as covariates for analyses focusing on the
interactive effects of genotype with treatment assignment on outcome.
Effects of GABRA2 genotype on treatment outcomes
Any drinking (OR=1.002, CI95%=1.0015–1.0024, χ2=63.9, p<.0001) and heavy drinking
(OR=1.003, CI95%=1.0025–1.0035, χ2=130.9, p<.0001) were significantly predicted by the
linear effect of time. The predicted probabilities of drinking and heavy drinking were lowest
at the beginning of treatment and increased thereafter. Also, as expected, drinking
(OR=0.839, CI95%=0.824–0.855, χ2=353.5, p<.0001) and heavy drinking (OR=0.886,
CI95%=0.868–0.903, χ2=147.8, p<.0001) were lower in women than men. In addition, these
probabilities varied significantly across treatment arms (drinking: OR=0.497, CI95%=0.488–
0.506, χ2=5688.7, p<.0001; heavy drinking: OR=0.566, CI95%=0.556–0.578, χ2=3302.9, p<.
0001), with both measures of drinking being greater among patients recruited from
outpatient compared with aftercare settings. Treatment assignment was also a significant
predictor of outcomes (drinking: OR=1.198, CI95%=1.108–1.296, χ2=20.5, p<.0001; heavy
drinking: OR=1.494, CI95%=1.373–1.626, χ2=86.5, p<.0001). Both drinking outcomes were,
in general, least probable among patients assigned to TSF, more probable among those
assigned to MET, and most probable among those assigned to CBT. As shown in Figures 1
and 2, the linear change in drinking over time varied with the type of treatment (drinking:
OR=0.9997, CI95%=0.9995–0.9999, χ2=8.1, p<.0044; heavy drinking: OR=0.9993,
CI95%=0.9991–0.9995, χ2=31.8, p<.0001) in a complex pattern.
Importantly, GABRA2 genotype affected the average likelihood of drinking (OR=1.262,
CI95%=1.122–1.428, χ2=15.0, p<.0001 and heavy drinking (OR=1.944, CI95%=1.714–2.206,
χ2=106.8, p<.0001), with an elevated probability of both occurring among patients with the
high-risk genotype. Genotype also altered the effects of treatment, albeit in a complex
manner, for both drinking (OR=0.855, CI95%=0.809–0.904, χ2=30.0, p<.0001) and heavy
drinking (OR=0.734, CI95%=0.692–0.779, χ2=102.3, p<.0001) outcomes. Figures 1 and 2
illustrate an interesting relation wherein greater differentiation of treatment type is seen in
patients possessing the low-risk (i.e., A/A) GABRA2 genotype.
DISCUSSION
Poor outcomes following treatment for alcohol dependence are common, and efforts to
improve the efficacy of treatment have become an integral part of treatment design (Daley
and Marlatt 1997; Larimer et al., 1999). In outcome studies of alcoholics, for example,
approximately 65–70% of patients relapse within one year of treatment, with the majority of
relapses occurring within the first three months (Miller et al., 2001,). Project MATCH
(Babor and Del Boca, 2003) was inspired by these concerns, and asked whether the
outcomes from three specific types of treatment, viz. CBT, TSF, and MET, would vary as a
function of the post hoc matching of their unique elements (i.e., cognitive restructuring with
relapse prevention skills in CBT vs. a strong abstinence message encouraged by group
fellowship in TSF vs. a non-confrontational motivational message in MET) with specific
patient characteristics.
The patient variables chosen for inclusion in the Project MATCH analyses were drawn from
a longer list of clinical and psychological variables that had predicted treatment outcome in
studies published prior to 1993 [(Project MATCH Research Group 1993); see (Ciraulo et al.,
2003) for a more recent review]. The list included, for example, a high level of alcohol
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involvement or dependence (Booth et al., 1991; Haver and Gjestad 2005; Langenbucher et
al., 1996; McLellan et al., 1994; Powell et al., 1998; Salloum et al., 2005; Winterer et al.,
1998; Woody et al., 1984). Alcohol involvement is typically quantified with scores on
alcohol problem scales, DSM symptom counts, duration of drinking, or the number of
previous treatments.
The list also included a select subset of comorbid psychiatric disorders. Of particular
interest, because of its strong association with poor treatment outcome, was Antisocial
Personality Disorder (ASPD), in which severe childhood conduct problems and adult
antisocial behaviors are conjointly present (Pettinati et al., 1999; Powell et al., 1998).
Comorbid anxiety or depressive disorders were not directly examined, for their association
with poor outcome (Hatsukami and Pickens 1982; Haver and Gjestad 2005; Kushner et al.,
2005; Magura et al., 2005; Willinger et al., 2002) appeared, at the time, to be highly variable
and complicated by other factors, including the gender and age composition of the patient
sample, as well as the preferred drug of abuse (Bobo et al., 1998; Brown et al., 1998;
Hesselbrock 1991; Hodgins et al., 1999; Kranzler et al., 1996; Rounsaville et al., 1986;
Sellman and Joyce 1996; Ziedonis and Kosten, 1991). Instead, a summary measure of
general psychiatric severity was employed in the analysis.
Unfortunately, tests of these and many other treatment matching characteristics showed no
significant interactions between the characteristic and type of treatment, during the active
treatment phase (Project MATCH Research Group, 1998). During the one-year post-
treatment phase, one primary matching variable, psychiatric severity, interacted significantly
with treatment. In the outpatient study, patients low on psychiatric severity had more
abstinent days after TSF than after CBT (Project MATCH Research Group, 1997). During
the post-treatment phase, two secondary matching variables were also significant:
outpatients who were high in anger and treated with MET had better post-treatment drinking
outcomes than those receiving CBT; and aftercare patients high in alcohol dependence
severity had better post-treatment outcomes after receiving TSF, while patients with low
severity of dependence did better with CBT (Project MATCH Research Group, 1997).
A question never asked in the outcome prediction literature before or during the era of
Project MATCH was whether genotype could be used as an objective predictor of risk. The
failure to consider genetic factors was understandable at the time, because until 2004
(Covault et al., 2004; Edenberg et al., 2004), the only candidate genes that had been reliably
associated with either the emergence or re-emergence of alcohol dependence were those
encoding proteins involved in alcohol metabolism, variation in which is most evident in
populations in the Far East (Gelernter and Kranzler, in press), although it is now known to
be very important in other populations as well (e.g., Luo et al., 2006). In addition, there was
no direct evidence suggesting that relapse risk was a stable trait, other than anecdotal reports
of so-called “revolving-door” alcoholics or recidivist DUI offenders, for whom treatment
entry followed by rapid treatment failure can become a stable pattern (Tait et al., 2002). Yet,
one might have discerned an involvement of genetic factors from the evidence available
associating poor treatment outcome with ASPD. The high heritability of ASPD has been
recognized for many years (e.g., Cadoret, 1978; Gelhorn et al., 2005; Grove et al., 1990;
Hicks et al., 2004; Slutske, 2001).
To date, only one published study has associated a candidate gene with alcohol treatment
outcome. Wojnar and colleagues (2006) analyzed genotype frequencies of the HTR1A
serotonin receptor gene and discovered an excess prevalence of the G/G versus C/C
genotype among patients who would later relapse. Although their results are intriguing, the
sample size was small (N=90). Furthermore, HTR1A has not yet been associated with other
known and heritable risk factors for relapse other than suicidality (Wojnar et al., 2006,).
Bauer et al. Page 6
Alcohol Clin Exp Res. Author manuscript; available in PMC 2011 September 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In the present study, we focused our analysis on the GABRA2 gene. Several reasons justified
the decision. GABRA2 has, for example, been associated with risk for alcohol dependence in
six independent studies (Covault et al., 2004; Edenberg et al., 2004; Enoch et al., 2006; Fehr
et al., 2006; Lappalainen et al., 2005; Soyka et al., 2007). In addition, it has been reliably
associated with both Conduct Disorder problems (Dick et al., 2006) and the amount of fast β
activity (Edenberg et al., 2004,) in the electroencephalogram. Both of these variables have
been associated with an elevated risk for poor treatment outcome (Bauer, 1994; Bauer, 2001;
Pettinati et al., 1999; Powell et al., 1998; Saletu-Zyhlarz et al., 2004; Winterer et al., 1998).
The results of our analysis of GABRA2 yielded several findings. A principal finding was a
significantly elevated probability of drinking and heavy drinking among patients with the
high-risk genotype. This finding was not evident in the analysis of percent days abstinent
and drinks per drinking day measured during the pre-treatment period (Table 1). The
discrepancy can be explained by the limited validity of self-reported (Wish et al., 1997;
Williams and Nowatzki, 2005) substance use at the time of treatment entry. In Project
MATCH and other treatment studies, retrospective recall of drinking behavior during the
pretreatment period may, therefore, be less accurate than recall during the treatment and
post-treatment periods, which occur after the patient has been asked to carefully monitor his/
her drinking behavior. In short, the daily probabilities of drinking and heavy drinking may
exhibit less error over time and may therefore be more powerful metrics. The significant
main effect of GABRA2 genotype and of the other independent variables revealed by our
analyses must be interpreted cautiously, because they are embedded within a series of
statistically significant interactions. In addition, several of these main and interaction effects,
though statistically significant, were associated with ORs that indicated modest effects.
Therefore, their clinical significance may not be as robust as their statistical significance.
We must also be cautious in comparing the present significant effects to the original,
generally non-significant effects demonstrated by Project MATCH. It is important to be
mindful that the present analysis is based on a homogenous sub-sample of Project MATCH
patients, i.e., European-Americans that provided DNA. Also, the original Project MATCH
analyses focused on percent days abstinent over a 90-day period as the primary outcome
measure whereas these analyses focused on daily estimates of any drinking and heavy
drinking over a much longer time period.
Figures 1 and 2 illustrate the complex pattern of results. The simplest description of the
results is that the high-risk allele blunts the variability in outcome associated with the three
different psychosocial treatments, whereas the low-risk allele permits better differentiation
of the effects of psychosocial treatments and, particularly, of TSF. The explanation for this
pattern of results is less clear and presently speculative. The root cause may involve an
enhancing effect of the high-risk allele on anxiety level (Enoch et al., 2006) or conduct
problems (Dick et al., 2006), which may, in turn, distract patients from attending to the
specific aspects of a treatment that differentiate it from other treatments. Alternatively, the
interaction may suggest that enhanced anxiety or conduct problems in these patients
selectively compromise the beneficial effects of TSF. Because TSF emphasizes total alcohol
abstinence, patients with greater anxiety or conduct problems may be more likely to fail TSF
than other treatments as a result of their greater stress reactivity and impulsivity. Or, patients
with higher levels of anxiety or conduct problems may benefit less from the group affiliation
and peer support that are integral and unique to implementation of the goals of TSF.
In summary, the present results offer an interesting insight and suggest a potential role for
genetic vulnerability not only in promoting the emergence of problem drinking (Covault et
al., 2004; Edenberg et al., 2004; Enoch et al., 2006; Fehr et al., 2006; Lappalainen et al.,
2005; Soyka et al., 2007), but also in promoting continued drinking after psychosocial
treatment. In addition, genetic vulnerability diminished the relative superiority of TSF over
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MET and CBT in suppressing alcohol use. The implications of these findings for future
treatment matching studies should be considered. For example, the findings suggest that
patients possessing the low-risk GABRA2 genotype, though drinking at a lower average
level, will show more variability in drinking outcomes and may therefore be better
candidates for studies of psychosocial treatments that address their psychosocial issues. In
contrast, patients possessing high-risk GABRA2 genotypes may be better candidates for
other (or additional) forms of treatment, e.g., medications such as naltrexone, acamprosate,
or topiramate, which could address their neurobiological differences.
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Figure 1.
Daily probability of drinking during and after the 12-week treatment period as a function of
genotype (high-risk = A/G or G/G; low-risk = A/A) and treatment assignment (CBT =
Cognitive-Behavioral Treatment, MET = Motivational Enhancement Therapy, TSF =
Twelve-Step Facilitation).
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Figure 2.
Daily probability of heavy drinking (men: > 5; women: > 4) during and after treatment as a
function of genotype (high-risk = A/G or G/G; low-risk = A/A) and treatment assignment
(CBT = Cognitive-Behavioral Treatment, MET = Motivational Enhancement Therapy, TSF
= Twelve-Step Facilitation).
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